Literature DB >> 25972389

A decision model for the watch-and-wait strategy in systemic sclerosis-associated interstitial lung disease.

Hyun Mi Kwon1, Eun Ha Kang1, Jin Kyun Park1, Dong Jin Go1, Eun Young Lee1, Yeong Wook Song1, Hyun-Ju Lee2, Eun Bong Lee3.   

Abstract

OBJECTIVE: To develop a decision model to identify SSc-associated interstitial lung disease (ILD) patients who are eligible for watchful waiting at ILD diagnosis.
METHODS: One hundred and fifty-one SSc-ILD patients who received medical care at Seoul National University Hospital from 1986 to 2013 were enrolled in this retrospective cohort study. ILD was diagnosed by chest CT. Patients with and without immunosuppressive treatment were compared in terms of characteristics at ILD diagnosis to identify distinguishing variables. After multivariate analysis, a decision model for watchful waiting was formulated. Its validity was assessed by comparing the survival of patients whose management in real practice did and did not accord with the management recommended by the model.
RESULTS: The untreated group had better survival than the immunosuppressive treatment group (P = 0.0316, by log-rank test). The untreated group was less likely to have gastrointestinal involvement (P = 0.008) and pulmonary arterial hypertension (PAH), as determined by echocardiography) (P = 0.015) and more likely to have favourable initial forced vital capacity (P = 0.0004), favourable initial lung diffusion capacity for carbon monoxide (P = 0.0002) and a low CT grade (P < 0.001). The final watchful waiting decision model included lack of PAH and limited ILD extent on CT. Application of the model to the cohort revealed that patients who were eligible for watchful waiting (as determined by the model) and underwent this management strategy had better survival than eligible patients who underwent immunosuppressive treatment (P = 0.048, by log-rank test).
CONCLUSION: Watchful waiting may be effective for SSc-ILD patients who have minimal pulmonary involvement on CT and lack PAH on echocardiography at baseline.
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  decision model; immunosuppressive treatment; interstitial lung disease; systemic sclerosis

Mesh:

Substances:

Year:  2015        PMID: 25972389     DOI: 10.1093/rheumatology/kev121

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  4 in total

Review 1.  Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management.

Authors:  Małgorzata Chowaniec; Marta Skoczyńska; Renata Sokolik; Piotr Wiland
Journal:  Reumatologia       Date:  2018-08-31

2.  Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease.

Authors:  Jeong Seok Lee; Eun Young Lee; You-Jung Ha; Eun Ha Kang; Yun Jong Lee; Yeong Wook Song
Journal:  Arthritis Res Ther       Date:  2019-02-14       Impact factor: 5.156

3.  Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort.

Authors:  S Panopoulos; Κ Chatzidionysiou; M G Tektonidou; V K Bournia; A A Drosos; Stamatis-Nick C Liossis; T Dimitroulas; L Sakkas; D Boumpas; P V Voulgari; D Daoussis; K Thomas; G Georgiopoulos; G Vosvotekas; Α Garyfallos; P Sidiropoulos; G Bertsias; D Vassilopoulos; P P Sfikakis
Journal:  Arthritis Res Ther       Date:  2020-03-23       Impact factor: 5.156

Review 4.  Pharmacological Interventions for Pulmonary Involvement in Rheumatic Diseases.

Authors:  Eun Ha Kang; Yeong Wook Song
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.